What This Bill Does · Plain English
Summary
Plain-English summary not yet available for this bill. Check back after our next analysis run.
Action Timeline
2023-12-22
Referred to the House Committee on Armed Services.
2023-12-22
Introduced in House
2023-12-22
Introduced in House
Frequently Asked Questions
Did HR.6895 pass?
HR.6895 did not pass and is no longer active. Final stage: COMMITTEE.
Full Bill Text
118 HR 6895 IH: Defense Production and Active Pharmaceutical Ingredients Act U.S. House of Representatives 2023-12-22 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. I 118th CONGRESS 1st Session H. R. 6895 IN THE HOUSE OF REPRESENTATIVES December 22, 2023 Ms. Slotkin introduced the following bill; which was referred to the Committee on Armed Services A BILL To amend the National Defense Authorization Act for Fiscal Year 2023 to extend Federal support for bioindustrial manufacturing processes to include support for the manufacturing of certain pharmaceutical ingredients. 1. Short title This Act may be cited as the Defense Production and Active Pharmaceutical Ingredients Act . 2. Modification of support for research and development of bioindustrial manufacturing processes Section 215(c)(1) of the James M. Inhofe National Defense Authorization Act for Fiscal Year 2023 ( Public Law 117–263 ; 10 U.S.C. 4841 note) is amended by inserting active pharmaceutical ingredients, key starting materials for such ingredients, after commodity chemicals, .
Loading intelligence layer…